U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H22O3
Molecular Weight 286.3655
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 4-HYDROXYESTRONE

SMILES

[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C(O)=C(O)C=C4

InChI

InChIKey=XQZVQQZZOVBNLU-QDTBLXIISA-N
InChI=1S/C18H22O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h4,6,11-12,14,19,21H,2-3,5,7-9H2,1H3/t11-,12-,14+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H22O3
Molecular Weight 286.3655
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

4-Hydroxyestrone (4-OHE1) is a carcinogenic metabolite originating from 17beta-estradiol (17β-E2) hormone. 4-OHE1 was a partial estrogen agonist on cancellous bone turnover, similar to 17β-E2, is able to emit electrons from its excited singlet state. The quantum yield is nearly the same like this of 17β-E2 and decreases with increasing substrate concentration, but enhances with temperature. The 4-OHE1 transient derived from the electron ejection process is leading to the formation of a secondary metabolite by reaction with the present C2H4OH radical. This fact indicates, that depending on the life habits of a person, a variety of metabolites can be formed, also such initiating cancer.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
3MN57C55S2
Record Status Validated (UNII)
Record Version